Redcare Pharmacy Publishes Q3 2026 Earnings Call Transcript

By Public Technologies
  • Redcare Pharmacy held its October 29, 2026, third-quarter earnings call with CEO Peter Schmid von Linstow and CFO Hendrik Krampe.
  • Management reaffirmed full-year guidance, targeting positive free cash flow in 2027; cash flow will remain negative in 2026.
  • German prescription revenue grew 56% in the third quarter; October growth slowed below 50%, in line with expectations.
  • October nonprescription revenue growth is expected below 10%, reflecting a slow start to cough-and-cold sales.
  • Third-quarter adjusted EBITDA margin rose 100 basis points to 3.4%; EBITDA reached EUR 12 million versus a EUR 2 million loss.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redcare Pharmacy NV published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk